Teladoc Health Raises FY2026 GAAP EPS Guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) Est; Lowers FY2026 Sales Guidance from $2.481B-$2.576B to $2.362B-$2.447B vs $2.508B Est

Teladoc Health (NYSE:TDOC) raises FY2026 GAAP EPS guidance from $(1.05)-$(0.75) to $(1.00)-$(0.75) vs $(0.92) analyst estimate. Lowers FY2026 sales outlook from $2.481 billion-$2.576 billion to $2.362 billion-$2.447 billion vs $2.508 billion estimate.